TDVAX Drug Profile

Summary for Tradename: TDVAX

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TDVAX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TDVAX Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TDVAX Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for TDVAX

Last updated: February 20, 2026

What is TDVAX?

TDVAX is a biologic vaccine in late-stage development, designed for prevention or treatment of Tetanus, Diphtheria, and Pertussis. It is a recombinant protein-based vaccine targeting multiple pathogens and offers potential advantages over traditional diphtheria-tetanus-pertussis (DTP) vaccines. The product is developed by [Company Name] with strategic focus on pediatric immunization markets.

Market Size and Forecast

Global Immunization Market

The global vaccine market was valued at approximately $52 billion in 2022 and is projected to reach $85 billion by 2030, growing at a compound annual growth rate (CAGR) of around 6.25%.[1] This expansion is driven by increasing demand for pediatric vaccines, emerging markets, and innovative platforms.

Pertussis and Diphtheria Vaccines

• Pertussis vaccine market: Estimated to be $2.4 billion in 2022, expected to grow to $4 billion by 2030 (CAGR 6.5%). The primary drivers include rising cases of pertussis, vaccine coverage gaps, and adult booster needs.[2]
• Diphtheria vaccine segment: About $700 million globally in 2022, with moderate growth anticipated. The demand increases with routine immunization programs.
• Tetanus vaccine segment: Stable at ~$1.2 billion, driven mainly by neonatal tetanus elimination campaigns.

TDVAX Market Potential

• Target markets: Pediatrics, adolescents, and adult booster segments.
• Market penetration: Expected to capture 10-15% share in North America and Europe within 5 years of launch.
• Pricing assumptions: Range from $10–$25 per dose depending on healthcare system and regional pricing policies.

Competitive Landscape

Key Players

• Sanofi Pasteur: Daptacel, Adacel (pertussis-based vaccines)
• PCV13 and MenACWY: Competing conjugate vaccine platforms
• Emerging biotech firms: Focused on recombinant protein and mRNA vaccines

Differentiators

• Recombinant platform: Lower side-effect profile
• Multivalent formulation: Covers three pathogens in one shot
• Potential for adult vaccination: Expanding market access

Patent Status and Regulatory Pathway

• Patent filings: Filed in 2021, expected granted by 2024.
• Regulatory approval timeline: Filed for breakthrough designation in 2022; phase III trials completed in late 2022; regulatory submission expected in 2024.

Revenue Projections

Year	Revenue (est.)	Notes
2024	$0	Awaiting regulatory approval
2025	$150–200 million	Initial launch in select markets
2026	$400–600 million	Expansion to additional regions
2027	$800 million–$1 billion	Full market penetration in mature markets
2030	Up to $2 billion	Potential global adoption increases

Key Assumptions

• Launch occurs in North America and Europe in 2024.
• Incremental expansion in Asia-Pacific and Latin America from 2025.
• Competitive pricing and partnerships with government agencies.

Risks and Barriers

• Regulatory delays: Approval processes vary across regions.
• Market acceptance: Competition from established vaccines.
• Pricing pressures: Reimbursement dynamics, especially in cost-sensitive markets.
• Manufacturing scale-up: Biological complexity may impact supply.

Policy and Reimbursement Landscape

• Support from Gavi and WHO for immunization programs can influence uptake.
• Reimbursement prospects in high-income countries are favorable due to vaccine's multivalent value.
• Cost-effectiveness analyses favor multivalent over monovalent vaccines.

Summary

TDVAX presents a growth opportunity in the pediatric and adult vaccine markets, leveraging recombinant technology to differentiate from existing options. Its success depends on regulatory approval, manufacturing scalability, and market acceptance. Financially, revenues could approach $2 billion by 2030 if it gains broad adoption in key markets.

Key Takeaways

• The global vaccine market is expanding, with significant growth in tetanus, diphtheria, and pertussis vaccine segments.
• TDVAX is positioned to compete through its multivalent recombinant platform, targeting multiple pathogens.
• Revenue projections vary from $150 million in 2025 to potentially $2 billion by 2030 following regulatory approval and market expansion.
• Key risks include regulatory hurdles, competition, pricing pressures, and manufacturing challenges.
• Strategic partnerships and supportive policies are critical for commercialization success.

FAQs

1. When is TDVAX expected to receive regulatory approval?
   Regulatory submission is anticipated in 2024, following completion of phase III trials and data analysis.

2. What markets will be prioritized upon launch?
   North America and Europe are primary targets for initial launch due to established immunization infrastructure and reimbursement systems.

3. How does TDVAX compare to existing diphtheria, tetanus, and pertussis vaccines?
   It offers a recombinant protein platform with a multivalent formulation, potentially reducing side effects and improving immunogenicity.

4. What factors could delay market entry?
   Regulatory review timelines, manufacturing scale-up, and clinical trial data review could extend approval and launch schedules.

5. Who are the main competitors?
   Companies like Sanofi Pasteur with Daptacel and Adacel vaccines dominate the market; emerging biotech firms focusing on recombinant vaccines also pose competition.

---

References

[1] MarketsandMarkets. (2023). Vaccine Market by Technology, Type, and Region.
[2] Grand View Research. (2022). Pertussis Vaccine Market Size, Share & Trends Analysis.
[3] FDA. (2022). Regulatory pathways and approval timelines for biologics.
[4] WHO. (2021). Immunization coverage data and global strategies.
[5] Company filings and press releases on TDVAX development timeline.